Literature DB >> 31390057

Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma.

Lucian R Chirieac1, Yin P Hung1,2, Wai Chin Foo1,3, Matthias D Hofer1,4, Paul A VanderLaan1,5, William G Richards6, David J Sugarbaker6, Raphael Bueno6.   

Abstract

BACKGROUND: The classification of diffuse malignant mesothelioma into epithelioid, biphasic, and sarcomatoid types is based on histologic patterns. The diagnosis is made on biopsies, and because of intratumoral heterogeneity, they may not be representative of the entire tumor. The number and volume of biopsies needed to reach diagnostic accuracy in diffuse malignant mesothelioma and their prognostic value remain unclear.
METHODS: This study examined 759 consecutive patients with pleural diffuse malignant mesothelioma treated by pleurectomy/decortication or extrapleural pneumonectomy for the presence of epithelioid and/or sarcomatoid histology and classified both the presurgery biopsies (core-needle or thoracoscopic) and surgical resection specimens. The number and volume of biopsies were correlated with pre- and postsurgery histologies and overall survival.
RESULTS: Diffuse malignant mesothelioma was classified as epithelioid (76%), biphasic (18%), sarcomatoid (5%), or indeterminate (1%) in biopsies and as epithelioid (64%), biphasic (32%), and sarcomatoid (4%) in surgical resection specimens (overall concordance, 80.6%). The positive likelihood ratios were 2.4, 13.6, and 90.1 for biopsies with epithelioid, biphasic, and sarcomatoid histologies, respectively. Concordant histologies between biopsies and resections were associated with a higher number of biopsies (median tissue blocks for concordant histologies vs discordant histologies, 3 vs 2; P < .002) but were less associated with a higher volume (median, 1.2 vs 1.1 cm3 ; P = .06). In a multivariate analysis, overall survival was independently predicted by histology in the resection specimen (P < .0001) but not in the biopsy (P = .09).
CONCLUSIONS: In contrast to epithelioid histology, sarcomatoid histology in biopsies is highly accurate. Despite intratumoral heterogeneity, the accuracy of histologic classification increases with the number of tissue blocks examined, emphasizing the diagnostic value of extensive sampling by presurgery biopsies.
© 2019 American Cancer Society.

Entities:  

Keywords:  extrapleural pneumonectomy; malignant mesothelioma; pathology

Mesh:

Year:  2019        PMID: 31390057      PMCID: PMC7341068          DOI: 10.1002/cncr.32416

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

1.  Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.

Authors:  V W Rusch; E S Venkatraman
Journal:  Ann Thorac Surg       Date:  1999-11       Impact factor: 4.330

2.  NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Authors:  David S Ettinger; Douglas E Wood; Wallace Akerley; Lyudmila A Bazhenova; Hossein Borghaei; David Ross Camidge; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Thomas Dilling; Michael Dobelbower; Ramaswamy Govindan; Mark Hennon; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Rudy P Lackner; Michael Lanuti; Rogerio Lilenbaum; Jules Lin; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; Neelesh Sharma; Scott J Swanson; James Stevenson; Kurt Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2016-07       Impact factor: 11.908

3.  Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy.

Authors:  David J Sugarbaker; Andrea S Wolf; Lucian R Chirieac; John J Godleski; Tamara R Tilleman; Michael T Jaklitsch; Raphael Bueno; William G Richards
Journal:  Eur J Cardiothorac Surg       Date:  2011-02-09       Impact factor: 4.191

Review 4.  Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.

Authors:  Raphael Bueno; Jason Reblando; Jonathan Glickman; Michael T Jaklitsch; Jeanne M Lukanich; David J Sugarbaker
Journal:  Ann Thorac Surg       Date:  2004-11       Impact factor: 4.330

5.  Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma.

Authors:  Laurent Greillier; Arnaud Cavailles; Anne Fraticelli; Arnaud Scherpereel; Fabrice Barlesi; Gianfranco Tassi; Pascal Thomas; Philippe Astoul
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

6.  The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura.

Authors:  H D Beauchamp; N K Kundra; R Aranson; F Chong; K F MacDonnell
Journal:  Chest       Date:  1992-10       Impact factor: 9.410

7.  Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center.

Authors:  Raja M Flores; Maureen Zakowski; Ennapadam Venkatraman; Lee Krug; Kenneth Rosenzweig; Joseph Dycoco; Catherine Lee; Cindy Yeoh; Manjit Bains; Valerie Rusch
Journal:  J Thorac Oncol       Date:  2007-10       Impact factor: 15.609

8.  The comparative accuracy of different pleural biopsy techniques in the diagnosis of malignant mesothelioma.

Authors:  R L Attanoos; A R Gibbs
Journal:  Histopathology       Date:  2008-07-18       Impact factor: 5.087

9.  Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.

Authors:  D J Sugarbaker; G M Strauss; T J Lynch; W Richards; S J Mentzer; T H Lee; J M Corson; K H Antman
Journal:  J Clin Oncol       Date:  1993-06       Impact factor: 44.544

10.  The European mesothelioma epidemic.

Authors:  J Peto; A Decarli; C La Vecchia; F Levi; E Negri
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  6 in total

Review 1.  Challenges in lung and thoracic pathology: molecular advances in the classification of pleural mesotheliomas.

Authors:  Lynnette Fernandez-Cuesta; Lise Mangiante; Nicolas Alcala; Matthieu Foll
Journal:  Virchows Arch       Date:  2021-01-07       Impact factor: 4.064

2.  Rethought histologic classification of pleural mesothelioma to better treat: go forward from looking back.

Authors:  Philippe Astoul
Journal:  Transl Lung Cancer Res       Date:  2020-08

Review 3.  Current Management and Future Perspective in Pleural Mesothelioma.

Authors:  Rajiv Shah; Laura V Klotz; Julia Glade
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.639

4.  Contrast-enhanced ultrasound guided pleural biopsy improves diagnostic confidence for pleural based lesions: a 3-year prospective study.

Authors:  Wenwen Sun; Yiming Zhou; Cong Yang; Zhengwei Dong; ZheMin Zhang; Yin Wang; Lin Fan
Journal:  BMC Pulm Med       Date:  2021-07-12       Impact factor: 3.317

5.  Gene Expression Analysis of Biphasic Pleural Mesothelioma: New Potential Diagnostic and Prognostic Markers.

Authors:  Rossella Bruno; Anello Marcello Poma; Greta Alì; Claudia Distefano; Agnese Proietti; Antonio Chella; Marco Lucchi; Franca Melfi; Renato Franco; Gabriella Fontanini
Journal:  Diagnostics (Basel)       Date:  2022-03-10

6.  Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma.

Authors:  Clément Meiller; François Montagne; Theo Z Hirsch; Stefano Caruso; Julien de Wolf; Quentin Bayard; Jean-Baptiste Assié; Léa Meunier; Yuna Blum; Lisa Quetel; Laure Gibault; Ecaterina Pintilie; Cécile Badoual; Sarah Humez; Françoise Galateau-Sallé; Marie-Christine Copin; Eric Letouzé; Arnaud Scherpereel; Jessica Zucman-Rossi; Françoise Le Pimpec-Barthes; Marie-Claude Jaurand; Didier Jean
Journal:  Genome Med       Date:  2021-07-14       Impact factor: 11.117

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.